US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

ENLV Enlivex Therapeutics Ltd

1.36

0.0101 (0.75%)

31 May 2024 - Cerrado

Retrasado por 15 minutos

Yet Another Biotech Stock Has Found Success During Tuesday's Session

It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech...

To read the full story on AllPennyStocks.com, click here.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Enlivex Therapeutics.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Enlivex Therapeutics.

Noticias sobre Enlivex Therapeutics Ltd ENLV

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 29 de Mayo 2024 (3 días hace) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Miércoles 29 de Mayo 2024 (3 días hace) • Edgar (US Regulatory)

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Miércoles 29 de Mayo 2024 (3 días hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martes 28 de Mayo 2024 (5 días hace) • Edgar (US Regulatory)

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Martes 28 de Mayo 2024 (5 días hace) • GlobeNewswire Inc.

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Lunes 29 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Lunes 22 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Yet Another Biotech Stock Has Found Success During Tuesday's Session
Martes 16 de Abril 2024 (2 meses hace) • AllPennyStocks.com

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Martes 16 de Abril 2024 (2 meses hace) • GlobeNewswire Inc.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Jueves 11 de Abril 2024 (2 meses hace) • GlobeNewswire Inc.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Jueves 11 de Abril 2024 (2 meses hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 7 de Febrero 2024 (4 meses hace) • Edgar (US Regulatory)

Más de Enlivex Therapeutics Ltd Artículos de Noticias

Gabelli Utility

Consolidated Edison

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones